IN Brief:
- More than €20 million has been invested in the first phase of the Clermont-Ferrand biotechnology platform.
- The 5,000 m² facility combines fermentation, downstream processing, media preparation, and analytical capability.
- Its shared infrastructure is intended to move biotechnology projects from laboratory development towards validated industrial production.
Biotech Open Platform has begun operating its industrial biotechnology facility in Clermont-Ferrand, moving a project established in 2024 into active scale-up work for fermentation processes.
More than €20 million has been invested in the first phase of the 5,000 m² facility at Michelin Innovation Park — Cataroux. Its first advanced fermentation projects are already under way, with the platform open to start-ups, industrial companies, and research organisations developing biotechnology processes that need to move beyond laboratory conditions.
The site combines fermentation, downstream processing, media preparation, and analytical capability in one location. Its purpose is to provide the equipment and process support needed between laboratory development and commercial manufacturing, where apparently successful biological processes begin to encounter the less forgiving conditions of larger vessels and longer production campaigns.
Scale changes more than output. Mixing, oxygen transfer, heat removal, nutrient distribution, foam control, and process monitoring become progressively harder to manage as fermentation volume increases. A strain that performs consistently in a laboratory vessel can lose productivity when those conditions change, leaving scale-up as one of the most expensive points at which biotechnology projects can fail.
Downstream processing adds another layer of difficulty. Once fermentation is complete, the target molecule or ingredient still has to be separated, concentrated, purified, dried, or otherwise prepared to a specification that a customer can use. Yield losses during those stages can damage the economics of an otherwise productive fermentation process.
Biotech Open Platform has been designed to bring those operations together rather than treating fermentation as a standalone step. The site includes filtration, crystallisation, drying, and analytical systems alongside its fermentation infrastructure, allowing developers to examine the complete process rather than optimise one vessel while leaving recovery and purification unresolved.
The platform says projects can be developed from small quantities towards representative industrial output, giving customers enough material for application testing, validation, and customer qualification before committing to a full commercial plant. That intermediate scale is particularly relevant to food ingredients, where prospective buyers may need substantial samples before approving a new protein, enzyme, or functional ingredient for formulation work.
The facility has separate environments for food and non-food projects and is working towards ISO 22000 certification. Traceability and controlled handling are equally important because fermentation projects can involve proprietary strains, process parameters, and analytical data whose commercial value rests on keeping them confidential while still allowing joint development work to proceed.
Danone, Michelin, DMC Biotechnologies, Crédit Agricole Centre France, Clermont Auvergne Innovation, and Greentech created the platform, with public support also contributing to its development. The structure gives the site an unusually broad industrial base, spanning food, materials, biotechnology, finance, and research rather than tying its equipment to one product family.
The opening comes as European fermentation businesses increasingly confront the capital demands of physical production. Investment is concentrating around fermentation businesses moving towards scale-up, where vessels, downstream equipment, utilities, laboratories, and working capital consume substantially more funding than early laboratory development.
Shared infrastructure changes that calculation by allowing several developers to use industrial equipment without each building a dedicated pilot plant. It does not remove scale-up risk, but it can expose weaknesses in a process before a company commits substantially larger sums to commercial capacity.
The economics remain demanding. Fermentation developers still have to demonstrate reliable yields, manageable feedstock costs, repeatable downstream recovery, specification control, and sufficient customer demand to keep eventual production assets busy. Access to larger equipment is useful only when those technical results can be carried forward into a process that remains stable after transfer.
That makes the first projects entering Clermont-Ferrand more significant than the opening ceremony. The platform now has to show that its shared model can generate validated operating windows, representative product volumes, and process packages robust enough to move into commercial manufacture.
The equipment gap between a successful laboratory process and a producing factory has frustrated biotechnology companies for years. Biotech Open Platform is now operating squarely in that gap, where litres become cubic metres and scientific promise begins accumulating industrial costs.